Publication:
Role of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitus

dc.contributor.authorSanchis, Pilar
dc.contributor.authorRivera Irigoin, Rosmeri
dc.contributor.authorFortuny Marques, Regina
dc.contributor.authorRio-Bocos, Carlos
dc.contributor.authorMas-Gelabert, Miguel
dc.contributor.authorGonzalez-Freire, Marta
dc.contributor.authorGrases, Felix
dc.contributor.authorMasmiquel Comas, Lluis
dc.date.accessioned2024-09-13T09:14:45Z
dc.date.available2024-09-13T09:14:45Z
dc.date.issued2020-06-05
dc.description.abstractThe aim of this study was to evaluate the relationship between serum levels of advanced glycation end products (AGEs) and abdominal aortic calcification (AAC) in patients with type 2 diabetes mellitus (DM2). This was a prospective cross-sectional study. One-hundred and four consecutive patients with DM2 were given lateral lumbar X-rays in order to quantify abdominal aortic calcification (AAC). Circulating levels of AGEs and classical cardiovascular risk factors were determined. Clinical history was also registered. Patients with higher AGEs values had higher grades of aortic calcification and higher numbers of diabetic-related complications. Multivariate logistic regression analysis showed that being older, male and having high levels of AGEs and triglycerides were the independent risk factors associated to moderate-severe AAC when compared to no-mild AAC. Our results suggest that AGEs plays a role in the pathogenesis of aortic calcifications. In addition, the measurement of AGEs levels may be useful for assessing the severity of AAC in the setting of diabetic complications.en
dc.description.sponsorshipThis research was funded by Balearic Islands Government. Acknowledgments:MGF acknowledges funding by the Miguel Servet Program, Instituto de SaludCarlos III (ISCIII), Madrid. All authors acknowledge funding by the LIBERI program, Health Research Institute ofthe Balearic Islands (IdISBa), Palma de Mallorca.es_ES
dc.format.number6es_ES
dc.format.volume9es_ES
dc.identifier.citationSanchis P, Rivera R, Fortuny R, Río C, Mas-Gelabert M, Gonzalez-Freire M, et al. Role of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitus. J Clin Med. 2020;9(6).en
dc.identifier.doi10.3390/jcm9061751
dc.identifier.issn2077-0383
dc.identifier.journalJournal of clinical medicinees_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/18494
dc.identifier.pubmedID32516928es_ES
dc.identifier.puiL2004504640
dc.identifier.scopus2-s2.0-85094649366
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22973
dc.identifier.wos552482100001
dc.language.isoengen
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)
dc.relation.publisherversionhttps://doi.org/10.3390/jcm9061751en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleRole of Advanced Glycation End Products on Aortic Calcification in Patients with Type 2 Diabetes Mellitusen
dc.typeresearch articleen
dspace.entity.typePublication
relation.isPublisherOfPublication30293a55-0e53-431f-ae8c-14ab01127be9
relation.isPublisherOfPublication.latestForDiscovery30293a55-0e53-431f-ae8c-14ab01127be9

Files